EUCTR2012-002553-38-ES
Active, not recruiting
Not Applicable
Mesenchymal stem cell based therapy for the treatment of osteogenesis imperfecta - TERCELOI
Itziar Astigarraga Aguirre0 sitesApril 9, 2013
ConditionsOsteogenesis imperfecta (OI) is a rare genetic disorder with increased bone fragility of varying severity. In the majority of patients the disease is caused by mutations in collagen type I. Severe OI is characterized by osteopenia, frequent fractures, progressive deformity, short stature, loss of mobility, chronic pain and can lead to premature death. At present a cure does not exist.Therapeutic area: Body processes [G] - Cell Physiological Phenomena [G04]
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Osteogenesis imperfecta (OI) is a rare genetic disorder with increased bone fragility of varying severity. In the majority of patients the disease is caused by mutations in collagen type I. Severe OI is characterized by osteopenia, frequent fractures, progressive deformity, short stature, loss of mobility, chronic pain and can lead to premature death. At present a cure does not exist.
- Sponsor
- Itziar Astigarraga Aguirre
- Status
- Active, not recruiting
- Last Updated
- 12 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.\-Patient age: older than 6 months and younger than 12 years old.
- •2\.\-Patients with molecular confirmation of mutation in either COL1A1 or COL1A2 genes associated with severe deforming OI (type III).
- •3\.\-Patiens with HLA identical (that shared at least 5/6 antigens) siblings willing to donate bone marrow\-MSCs.
- •4\.\-All patients that fulfil the inclusion criteria regardless of whether or not they are undergoing biphosphonate treatment
- •5\.\-Patients whose parents or the legal guardians are willing to sign the consent forms to participate in this clinical trial.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 3
- •F.1\.2 Adults (18\-64 years) no
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) no
Exclusion Criteria
- •1\.\-Patient age: older than 12 years old
- •2\.\-Patients lacking confirmation of mutation in either COL1A1 or COL1A2 genes associated with severe deforming OI (type III).
- •3\.\-Other pathological subtypes of OI.
- •4\.\-Patiens lacking of HLA identical (that shared at least 5/6 antigens) siblings willing to donate bone marrow\-MSCs.
- •5\.\-Immunodeficiencies and any other malignancies
- •6\.\-Participation in other clinical trial
- •7\.\-Any medical or psychiatric condition that in the researcher?s opinion could affect the patient´s ability to complete the trial or hamper the participation in the trial.
- •8\.\-Patients whose parents or the legal guardians do not sign the consent forms
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Therapeutic effect of mesenchymal cells in patients suffering from a disease characterized by a severe inflammation and/or in whom the immune system attacks their own tissues.Crohn's diseaseMedDRA version: 14.0Level: LLTClassification code 10011402Term: Crohn's disease (colon)System Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 14.0Level: HLGTClassification code 10003816Term: Autoimmune disordersSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 14.0Level: PTClassification code 10064147Term: Gastrointestinal inflammationSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 14.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2011-005966-39-BECHU-ULg20
Recruiting
Phase 1
Cell therapy with use of mesenchymal stem cells in infertile women with Thin EndometriumIRCT20230222057500N1Tehran University of Medical Sciences10
Active, not recruiting
Not Applicable
Mesenchymal Stromal Cells (MSC) for the treatment of severe (grade II-IV) steroid-resistant Graft Versus Host Disease (GVHD): a phase I trial - MSC-GvHDGraft versus Host disease GvHD steroid resistantEUCTR2008-007869-23-ITAZIENDA OSPEDALIERA SAN GERARDO DI MONZA
Active, not recruiting
Phase 1
Infusion of mesenchymal stem cells as treatment for steroid resistant grade II to IV acute GVHD or poor graft function: a multicenter phase II studyEUCTR2007-004310-14-BECHU-ULG120
Withdrawn
Phase 2
Infusion of mesenchymal stem cells as treatment for steroid resistant grade II to IV acute GVHD or poor graft function: a multicenter phase II studymesenchymale stamcellen bij acute GvHD of onvoldoende functionerende greffeacute GvHDrejection1002432410018865NL-OMON31471Academisch Ziekenhuis Maastricht10